#Oncotarget reported (Han 2015) breast tumors were reduced by #trastuzumab when combined w/ DPAGT1 inhibitors, even in #Her2 negative cancers. @anviron.bsky.social confirmed this paradox, DPAGT1 inhibitor, ANV221, upregulated Her2 in #TNBC, opening door to potent, targeted TNBC therapeutics.